Triazolopyrazine derivatives

A compound of the formula I:

• wherein:
• R1 is selected from hydrogen, Br, Cl, F, —O(CH2)nCH3, —NR10C(O)OR12, —(CR12R13)nNR10R11, —O(CH2)nOR10, —(CH2)nOR10, —C(O)R10, —C(O)OR10, —C(O)NR10R11, —NR10R11, —S(O)2R10, —S(O)R10, —S(O)2NR10R11, —CF3, —CF2H, —NR10C(O)NR10R11, —NR10C(O)R11, —NR10S(O)2R11, —N(CH2)n(C3-C8 cycloalkyl), —ON, —NO2, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heteroalicyclic, 3-8 membered heteroalicyclic-(3-8 membered heteroalicyclic), 8-10 membered heterobicyclic, 5-7 membered heteroaryl, C6-C10 aryl, C2-C6 alkenyl, and C2-C6 alkynyl wherein C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heteroalicyclic, 8-10 membered heterobicyclic, 5-7 membered heteroaryl, C6-C10 aryl, C2-C6 alkenyl, and C2-C6 alkynyl are optionally substituted by one or more moieties selected from the group consisting of Br, Cl, F, —(CH2)nOH(OR10)CH3, —(CH2)nOR10, —(CH2)nO(CH3)2OR10, —O(O)R10, —O(O)OR10, —(CR10R11)nO(O)OR10, —C(O)NR10R11, —(CR10R11)O(O)NR10R11, —(CH2)nNR10R11, —S(O)2R10, —S(O)R10, —S(O)2NR10R11, —CF3, —CF2H, —(CH2)nNR10C(O)NR10R11, —(CH2)nNR10C(O)OR11, —NR10C(O)R11, —NR10C(O)OR11, —NR10S(O)2R11, —ON, —NO2, oxo, C1-C6 alkyl, C3-C8 cycloalkyl, —(CH2)n(3-8 membered heteroalicyclic), —(CH2)n(5-7 membered heteroaryl), —(C2)n(C6-C10 aryl), C2-C6 alkenyl, and C2-C6 alkynyl;
• R2 is H;
• R3 is selected from
• R10 and R11 are independently selected from H, —(CH2)nOR12, —(CH2)nC(CH3)2OR12, —CHR12(CH2)nOR13, —C(O)OR12, —(CH2)nCHR12OR13, —C(CH3)2(CH2)nOR12, —CH2CF2H, —(CH2)nC(CH3)2NR12R13, —(CH2)nNR12R13, —(CH2)nCHOR12(CH2)nOR13, —(CH2)n(NR12R13)C(O)NR12R13, —(CH2)nS(O)2R12, —(CH2)nC(O)NR12R13, —NR12(CH2)n(5-7 membered heteroaryl), —NR12(CH2)n(3-8 membered heterocycle), —(CH2)n(8-10 membered heterobicyclic), —(CH2)n(3-8 membered heteroalicyclic), C1-C6 alkyl, C3-C8 cycloalkyl, C6-C10 aryl, C2-C6 alkenyl, 3-8 membered heteroalicyclic and C2-C6 alkynyl, wherein said 5-7 membered heteroaryl, 3-8 membered heterocycle and 8-10 membered heterobicyclic are optionally substituted by one or more moieties selected from the group consisting of —(CH2)nOR12, C1-C6 alkyl, C3-C8 cycloalkyl, C6-C10 aryl, C2-C6 alkenyl, 3-8 membered heteroalicyclic and C2-C6 alkynyl;
• or when R10 and R11 are attached to the same atom, R10 and R11 optionally combine to form a 3-8 membered heteroalicyclic ring;
• R12 and R13 are independently selected from H, C1-C6 alkyl, —C(O)CH3, C3-C8 cycloalkyl, C6-C10 aryl, C2-C6 alkenyl, 5-7 membered heteroaryl and C2-C6 alkynyl, wherein said 5-7 membered heteroaryl is optionally substituted by one or more moieties selected from the group consisting of C1-C6 alkyl, C3-C8 cycloalkyl, C6-C10 aryl, C2-C6 alkenyl, and C2-C6 alkynyl;
• or when R12 and R13 are attached to the same atom, R12 and R13 optionally combine to form a 3-8 membered heteroalicyclic ring;
• R4 is selected from the group consisting of hydrogen, and C1-C6 alkyl;
• and
• each n is independently 0, 1, 2, 3 or 4;
• wherein 3-8 membered heteroalicyclic and 3-8 membered heterocycle are independently selected from the group consisting of aziridinyl, oxetanyl, thiapanyl, azepanyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrolidinyl, tetrahydropyranyl, tetrahydrothioipyranyl, piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl, morpholinyl, 1,4-dithianyl, piperazinyl, 1,4-azathianyl, azepanyl, 1,4-oxaazepanyl, 1,4-dithiepanyl, 1,4-thieazapanyl, 1,4-diazepanyl, 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl, 1,2,3,4-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2-dihydropyridyl, and imidazolidinyl;
• wherein 8-10 membered heterobicyclic is selected from the group consisting of benzofuranyl, benzothiphenyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, isoindolyl, Quinolinyl, isoquinoliinyl, quinazolinyl, quinaxolinyl, indazolyl, purinyl, indolininyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, 3H-indolyl, indolyl, isoindolinyl, 2,3-dihydrobenzofuranyl, 1,3-dihydrobenzofuranyl, 1H-isoindolyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,2-dihydroquinoxalinyl, 1,2-dihydroquinazolinyl, 3,4-dihydroquinazolinyl, 3,3a-dihydropyrazolo[1,5-a]pyrimidinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazine, 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl, and 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine;
• wherein 5-7 membered heteroaryl is selected from the group consisting of pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, tetrazolyl, pyridinyl, pyridazinyl, and pyrimidinyl;
• or a pharmaceutically acceptable salt thereof.